EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Aceso Life Science Group Ltd (0474) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Aceso Life Science Group Ltd HK$0.24, price HK$0.14, upside +70.0%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Industrials · HK · ISIN KYG0070S1066

AL Thin data Oct 2, 2026

Aceso Life Science Group Ltd

0474 · HK

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

Fair value HK$0.2414 · Strongly undervalued (+70.0%)
Generates free cash flow
Ranks above peers (6/9)
Quality 49/100
Weak Growth (revenue 5y −28.6 %/yr in HKD)
High debt
Narrow moat 32/100
Thin data
⚠ Dilution
Watch Aceso Life Science Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.2270 HK$0.0180 Fair Value HK$0.2414 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range HK$0.0180 – HK$0.2270 · fair‑value band HK$0.0676 – HK$0.2941 · the HK$0.1420 price screens below the HK$0.2414 fair value. Dashed = 300-day average. As of Oct 2, 2026.

Follow Aceso Life Science Group in your weekly email

Every Wednesday you see whether Aceso Life Science Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom.

Show more

Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom. It operates through rental and sale of construction machinery and spare parts business; provision of repair and maintenance and transportation service business; money lending business; provision of asset management, securities brokerage and other financial service business; property leasing business; and property development business segments. The company leases and sells construction machinery, including crawler cranes, mobile cranes, aerial platforms, and foundation equipment, as well as spare parts; and sells construction materials. It also provides repair and maintenance services for construction machinery; transportation services, such as local container delivery, construction site delivery, and heavy machinery transport; mortgaged and personal loans; and money lending, asset management, commodities, futures, securities brokerage, and other financial services. In addition, the company retails men's and women's apparel; and provides group management, administration, and securities investment services. Further, the company involved in trading of futures and bioscience; and urban development businesses. The company was formerly known as Hao Tian Development Group Limited and changed its name to Aceso Life Science Group Limited in October 2020. Aceso Life Science Group Limited was founded in 1985 and is based in Wan Chai, Hong Kong.

Stock analysis

Aceso Life Science Group Ltd (0474) currently trades at HK$0.1420, while our model-based Fair Value estimate is HK$0.2414, implying the stock looks roughly 41.2% undervalued today.

Show more

Valuation

Bull case: the Earnings-Based group reads highest at a median of HK$1.34 per share, and 6 of the 8 models we run sit above the HK$0.1420 price.

Bear case: the Asset-Based group reads lowest at HK$0.0300, and 2 of the 8 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$0.0676 (bear) to HK$0.2941 (bull), the price of HK$0.1420 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Industrials sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Aceso Life Science Group Ltd reported revenue of HK$64.0M in FY2026 versus HK$315M in FY2022, a compound −32.9%/yr. Reported net income was HK$338M in FY2026.

Key figures

Market cap HK$1.3B (≈ $161M) · EPS (TTM) HK$0.0500 · Return on equity −71.6% · Return on assets (EBIT) −1.1% · Operating margin 154% · Revenue (TTM) −HK$59.0M · Revenue growth (YoY) +18.2% · Free cash flow HK$20.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 11% below its 52-week high and 125% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −12% fair-value upside, at 70%, 0474 screens cheaper than that median.

Fair Value models

Bear HK$0.0676 Fair Value HK$0.2414 Bull HK$0.2941
Price HK$0.1420 · Upside +70.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (HK$0.0256 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Growth DCF n/a n/a HK$0.0300 73
5Y P/E Exit HK$0.1500 HK$0.5300 HK$1.07 63
P/E Multiple HK$0.3700 HK$0.5000 HK$0.6200 63
All 9 models by family
DCF Models
5Y P/E Exit HK$0.1500 HK$0.5300 HK$1.07 63
10Y P/E Exit HK$0.0700 HK$0.3800 HK$0.9000 54
Earnings-Based
Graham-Dodd HK$0.2600 HK$1.81 HK$2.54 61
Lynch FV HK$0.9300 HK$1.34 HK$1.74 59
Multiples
P/E Multiple HK$0.3700 HK$0.5000 HK$0.6200 63
P/B Multiple HK$0.0500 HK$0.0700 HK$0.0900 55
Asset-Based
NCAV (Graham) HK$0.0300 HK$0.0300 HK$0.0500 54
Growth DCF
Growth DCF n/a n/a HK$0.0300 73
Economic Profit
Residual Income HK$0.1500 HK$0.2600 HK$0.6700 59

Open the full fair value analysis →

Notify me when 0474 reaches fair value

Put 0474 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 49 · Market factors (momentum, volatility) 75

Profitability 61
Margins and returns on capital today
Quality Growth 48
Are margins and returns improving?
Cashflow 75
Earnings quality: real cash, not paper profit
Fin. Strength 14
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 81
Price trend over the last 3–12 months (market factor)
52W Momentum 93
Distance to the 52-week high (market factor)
Net Issuance 6
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 23/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−67.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−41.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.6%
Start year 2021 (pandemic). Over 10 years: −6.8% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7.4% (2020) → −12.3% (2025)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+53.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +50.2% a year for the price.

Watch 0474, get fair value alerts →

Compare Aceso Life Science Group Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Rental & Leasing Services · 87 stocks

Beats the industry median on 6/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 49 · Above median
Fair Value upside +70.0% · Above median
Profitability
Return on assets −17.1% · Bottom 25%
Operating margin (TTM) 154.0% · Top 25%
Growth and dividend
Revenue growth 18.2% · Top 25%
Balance sheet
Debt / equity 2.50× · Highest 25%

Valuation Multiplesvs Rental & Leasing Services median · lower = cheaper

P/B 0.35× · Cheapest 25%
P/FCF 8.0× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 74
FUTURE (revenue growth)91 · sector 38
PAST (return on equity)0 · sector 30
HEALTH (low debt)0 · sector 63
DIVIDEND (yield)0 · sector 47

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Rental & Leasing Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
United Rentals, Inc URI $1,044 $441.48 −58%
Sunbelt Rentals Holdings SUNB $75.06 $65.76 −12%
AerCap Holdings AER $143.93 $208.22 +45%
U-Haul Holding UHAL $60.88 $7.57 −88%
Ryder System, Inc R $233.93 $151.59 −35%
Ayvens AYV €10.01 €26.14 +161%
Element Fleet Management Corp EFN C$23.85 C$21.30 −11%
GATX Corporation GATX $175.86 $129.05 −27%
BOC Aviation Limited 2588 HK$71.00 HK$146.00 +106%
EquipmentShare.com Inc EQPT $17.35 $3.89 −78%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aceso Life Science Group Ltd · Fair Value
HK$0.2414 +41%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Aceso Life Science Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/0474

Frequently asked questions

Is Aceso Life Science Group Ltd (0474) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of HK$0.2414 versus a price of HK$0.1420, about +70% upside (undervalued).
What is the fair value of 0474?
Our model-based fair value for Aceso Life Science Group Ltd is HK$0.2414 (as of Oct 2, 2026), built from audited fundamentals. The current price: HK$0.1420.
What is the quality score of 0474?
Aceso Life Science Group Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aceso Life Science Group Ltd (0474)?
Our model-based price target is the fair value of HK$0.2414 (as of Oct 2, 2026) from 9 valuation models. Cautious scenario HK$0.0676, optimistic scenario HK$0.2941. It is a calculation from audited fundamentals, not an analyst target.
What is the Aceso Life Science Group Ltd stock forecast for 2026?
Our models put fair value at HK$0.2414, about +70% upside versus a price of HK$0.1420 (undervalued). Cautious scenario HK$0.0676, optimistic scenario HK$0.2941. The calculation is refreshed regularly with new filings.
What growth is priced into Aceso Life Science Group Ltd (0474)?
For today's price to be fair in a discounted-cash-flow model, Aceso Life Science Group Ltd would have to grow free cash flow by +53.4 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -28.7 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of 0474 use?
Our models discount Aceso Life Science Group Ltd at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Aceso Life Science Group Ltd that is +53.4 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Aceso Life Science Group Ltd (0474) delivered so far?
Over the past 5 years revenue at Aceso Life Science Group Ltd grew -28.7 % a year. The price currently implies +53.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Aceso Life Science Group Ltd (0474) growing?
The median revenue growth in the sector is +9.4 % a year. That is the yardstick for the growth priced into Aceso Life Science Group Ltd (+53.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Aceso Life Science Group Ltd (0474)?
The free-cash-flow yield on the price is 1.58 %: that much free cash flow Aceso Life Science Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Aceso Life Science Group Ltd (0474)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aceso Life Science Group Ltd it is HK$0.2414 per share (as of Oct 2, 2026), against a price of HK$0.1420. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Aceso Life Science Group Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 0474 trades below its calculated fair value: price HK$0.1420, fair value HK$0.2414, a gap of about +70% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0474?
No. The price is what the market pays today (HK$0.1420); the fair value is what the company's own numbers justify (HK$0.2414). For Aceso Life Science Group Ltd the two are HK$0.0994 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aceso Life Science Group Ltd worth?
The market values Aceso Life Science Group Ltd at about HK$1.3B (market capitalisation, as of Oct 2, 2026). Per share that is HK$0.1420; our models calculate a fair value of HK$0.2414 per share.
What do the bullish and bearish scenarios say about 0474?
Our models span a range for Aceso Life Science Group Ltd: cautious scenario HK$0.0676, base HK$0.2414, optimistic HK$0.2941 per share (as of Oct 2, 2026, price HK$0.1420). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aceso Life Science Group Ltd (0474)?
Balance-sheet figures for Aceso Life Science Group Ltd (as of Oct 2, 2026): return on equity −71.6%, debt of 2.50 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 0474 from its 52-week high?
Aceso Life Science Group Ltd trades at HK$0.1420, about 11% below its 52-week high of HK$0.1600 and 125% above the low of HK$0.0630 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.2414 is for.
Which stocks are comparable to Aceso Life Science Group Ltd?
From the same area (Industrials) we also value United Rentals, Inc, Sunbelt Rentals Holdings, AerCap Holdings, U-Haul Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aceso Life Science Group Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price HK$0.1420, calculated fair value HK$0.2414 (+70%), Quality Score 49/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0474 calculated?
We run Aceso Life Science Group Ltd through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.2414, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Aceso Life Science Group Ltd currently trades 41 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aceso Life Science Group Ltd (0474)?
The closing price on Sep 30, 2026 was HK$0.1420. Our model-based fair value is HK$0.2414, about +70% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aceso Life Science Group Ltd right now?
The model range is unusually wide (HK$0.0676 to HK$0.2941). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (49/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Aceso Life Science Group Ltd

How large is the market capitalisation of Aceso Life Science Group Ltd (0474)?
The market capitalisation of Aceso Life Science Group Ltd is HK$1.3B (≈ $161M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Aceso Life Science Group Ltd (0474)?
Earnings per share at Aceso Life Science Group Ltd are HK$0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Aceso Life Science Group Ltd (0474)?
The return on equity (ROE) of Aceso Life Science Group Ltd is −71.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aceso Life Science Group Ltd (0474)?
On an EBIT basis the return on assets of Aceso Life Science Group Ltd is −1.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aceso Life Science Group Ltd (0474)?
The operating margin of Aceso Life Science Group Ltd is 154% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much revenue does Aceso Life Science Group Ltd (0474) generate?
Aceso Life Science Group Ltd generates revenue of −HK$59.0M (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How fast is revenue growing at Aceso Life Science Group Ltd (0474)?
Revenue at Aceso Life Science Group Ltd is growing +18.2% versus a year earlier (3y avg −41.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Aceso Life Science Group Ltd (0474) carry?
The net debt of Aceso Life Science Group Ltd is HK$1.0B (fiscal year 2026, ≈ 52.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Aceso Life Science Group Ltd in the live analysis

One click puts Aceso Life Science Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.